British Journal of Dermatology (BRIT J DERMATOL)

Publications in this journal

• Article: Genetic Associations of Psoriasis in a Pakistani Population

  P.A. Shaiq, P.E. Stuart, A. Latif, C. Schmotzer, A.H. Kazmi, M.S. Khan, M. Azam, T. Tejasvi, J.J. Voorhees, G.K. Raja, J.T. Elder, R. Qamar, R.P. Nair
  [show abstract] [hide abstract]
  ABSTRACT: Abstract Background Genetic predisposition to psoriasis, an inflammatory skin disease affecting 0.2 – 4% of world populations, is well established. Thus far, 41 psoriasis susceptibility loci reach genome-wide significance (p ≤ 5 x 10-8). Identification of genetic susceptibility loci in diverse populations will help understand the underlying biology of psoriasis susceptibility. Objectives The primary objective of this study is to examine psoriasis susceptibility associations previously reported in Chinese and Caucasian populations in a Pakistani cohort. Methods Blood samples and phenotype data were collected from psoriasis cases and controls in Islamabad, Pakistan. DNA was isolated and genotypes of selected susceptibility markers were determined. The data were analyzed by chi square tests or logistic regression for psoriasis association. Results HLA-Cw6 showed the strongest association (OR = 2.43, p = 2.3 x 10-12). HLA-Cw1 showed marginally significant association (OR = 1.66, p = 0.049), suggesting that the HLA-Cw1-B46 risk haplotype may be present in the Pakistani population. Three other loci (IL4/IL13, NOS2, TRAF3IP2) showed nominally significant association (p < 0.05). Conclusions HLA-Cw6 is strongly associated with psoriasis susceptibility in the Pakistani population, as has been found in every other population studied. In addition, HLA-Cw1 showed marginal association, reflecting the relative geographic proximity and thus likely genetic relatedness to other populations in which HLA-Cw1–B46 haplotype is known to be associated. A larger cohort and a denser marker set will be required for further analysis of psoriasis associations in the South Asian population.
  British Journal of Dermatology 03/2013;
• Article: The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. Huang YC, Li YC, Chen TJ. Br J Dermatol. 2012 Aug;167(2):424-32.

  Huang YC, Li YC, Chen TJ
  British Journal of Dermatology 07/2012; 167(2):424-32.
• Article: Interventions for treating oral lichen planus: a systematic review

  G. Lodi, M. Carrozzo, S. Furness� and K. Thongprasom
  British Journal of Dermatology 01/2012;
• Article: The distribution pattern of Segmental Vitiligo: clues for somatic mosaicism

  Nanja van Geel, Reinhart Speeckaert, Elodie Melsens, Marijn Speeckaert, Sofie De Schepper, Jo Lambert, Lieve Brochez
  [show abstract] [hide abstract]
  ABSTRACT: Background: Segmental vitiligo is characterized by a unilateral and localized distribution. So far, the underlying mechanism is still an enigma. Objective: To get insight in the etiopathogenesis of segmental vitiligo by comparing the distribution pattern of dermatoses with a possible mosaic or neurogenic background to segmental vitiligo. Methods: In this retrospective observational study the distribution pattern of 724 unilateral, linear or band shaped control lesions was compared to 181 segmental vitiligo lesions. Clinical photographs were used to score similarities according to a defined grading system (scale 0 for no similarities up to 4 for complete similarity). Control lesions were evaluated both individually and after grouping into different cell types. Results: In general, only in a minority of cases (36.9%), similarities (grade 1-4) were seen between control lesions and segmental vitiligo. Grade 2-4 similarities were mainly seen in segmental lentiginosis (73.7%) (P < 0.001). The best grade for correspondence (grade 3 to 4) was only significantly more observed in segmental lentiginosis (36.8% vs 3.5%, P < 0.001) and epidermal naevus verrucosus (12.5% vs 3.7%, P = 0.008) compared to the other control lesions. Segmental vitiligo was significantly associated with disorders originating from melanocytes. Conclusion: Our results demonstrate that the distribution pattern of segmental vitiligo is not entirely similar to another skin disease, although some mosaic skin disorders have more overlap with segmental vitiligo compared to others. The remarkable clinical similarity with several cases of mosaic diseases involving melanocytes support the hypothesis that cutaneous mosaicism may be involved in segmental vitiligo.
  British Journal of Dermatology 01/2012;
• Article: Medical Professional Involvement in Smartphone Apps in Dermatology.

  Hamilton AD, Brady RR
  British Journal of Dermatology 01/2012;
• Article: ok

  Fortuna G
  British Journal of Dermatology 01/2011;
• Article: An Ectodysplasin A receptor (EDAR) founder mutation results in a high frequency of the autosomal recessive form of Hypohidrotic Ectodermal Dysplasia in India

  M D Bashyam, A K Chaudhary, E C Reddy, V Reddy, V Acharya, H A Nagarajaram, A R R Devi, L Bashyam, A B Dalal, N Gupta, M Kabra, M Agarwal, S R Phadke, R Tainwala, R Kumar, S V Hariharan
  [show abstract] [hide abstract]
  ABSTRACT: Background: Hypohidrotic/anhydrotic ectodermal dysplasia (HED) is a rare mendelian disorder affecting ectodermal tissues. The disease is primarily caused by inactivation of any one of three genes viz. Ectodysplasin A1 (EDA-A1) which encodes a ligand belonging to the Tumor Necrosis Factor (TNF) super family; Ectodysplasin A receptor (EDAR) encoding the EDA-A1 receptor and Ectodysplasin A receptor associated death domain (EDARADD) encoding an adaptor protein. X-linked recessive (EDA-A1), the predominant form of HED, as well as autosomal recessive and dominant (EDAR and EDARADD) inheritance patterns have been identified in affected families. Objectives: To determine the common genes causing HED in India. Methods: We performed mutation analysis on twenty six HED families from India (including thirty patients). In addition, we carried out sequence and structure analysis of missense/nonsense and insertion/deletion mutations. Results: Among the twenty six families analysed, disease causing EDAR mutations were identified in twelve (46 %) while EDA-A1 mutations were detected in eleven (42 %). Four novel mutations in EDAR and five in EDA-A1 were identified. More importantly, a possible founder EDAR mutation viz. c.1144G>A was identified in five independent families thus accounting for about one-fifth of affected families in whom mutation was detected. A majority of EDA-A1 mutations localized to the TNF-like domain while the location of EDAR mutations was more widespread. Conclusions: This is the first report of a founder EDAR mutation and of a significantly high frequency of autosomal recessive HED
  British Journal of Dermatology 01/2011;
• Article: Poor long term outcome of severe alopecia areata in children treated with high dose pulse corticosteroid therapy.

  T Hubiche, C Léauté-Labrèze, A Taïeb, F Boralevi
  British Journal of Dermatology 06/2008; 158(5):1136-7.
• Article: Complementary and alternative medicine usage in rosacea.

  M A McAleer, F C Powell
  British Journal of Dermatology 06/2008; 158(5):1139-41.
• Article: Interstitial granulomatous drug reaction presenting as erythroderma: remission after discontinuation of enalapril maleate.

  Y-C Chen, C-H Hsiao, T-F Tsai
  British Journal of Dermatology 06/2008; 158(5):1143-5.
• Article: A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset.

  C T Derk, G Huaman, S A Jimenez
  [show abstract] [hide abstract]
  ABSTRACT: Several uncontrolled studies in systemic sclerosis have shown that D-penicillamine may cause improvement in skin sclerosis, decrease the rate of new visceral organ involvement, and improve overall survival. To undertake a single-centre retrospective randomly selected cohort study to examine the effects of D-penicillamine treatment on skin and visceral organ involvement in patients with rapidly progressive systemic sclerosis of recent onset. Eighty-four patients with diffuse cutaneous systemic sclerosis who had received D-penicillamine within 24 months of clinically detectable onset of skin sclerosis were randomly selected from the systemic sclerosis cohort followed at the Scleroderma Center of Thomas Jefferson University. Employing a previously described severity scale, disease severity and skin involvement were compared from initiation of D-penicillamine to end of study and a correlated matched t-test was used to establish statistical significance. At a mean+/-SD duration of D-penicillamine therapy of 29.2+/-5.5 months and at a median dose of 750 mg per day statistically significant improvement in skin (P<0.01) and cardiac, pulmonary and renal involvement (P<0.05) was observed. At last follow-up, 17 (20%) patients were still receiving D-penicillamine, 25 (30%) had discontinued it owing to disease improvement, and 18 (21%) had discontinued it owing to side-effects. In a population of patients with diffuse cutaneous systemic sclerosis, with progressive disease of recent onset, D-penicillamine treatment at a median dose of 750 mg per day caused a statistically significant reduction in skin involvement and improvement of renal, cardiac and pulmonary involvement.
  British Journal of Dermatology 06/2008; 158(5):1063-8.
• Article: Cutaneous graft-versus-host-like histology in childhood. Importance of clonality analysis in differential diagnosis. A case report.

  A D'hauw, M M B Seyger, P J T A Groenen, C M R Weemaes, A Warris, W A M Blokx
  British Journal of Dermatology 06/2008; 158(5):1153-6.
• Article: Nicorandil and ulcerations: a NAD/NADP and nicotinic acid-dependent side-effect?

  P Trechot, A Barbaud, N Petitpain, A Claeys, J-L Schmutz
  British Journal of Dermatology 06/2008; 158(5):1150-1.
• Article: Noninvasive biophysical assessments of the efficacy of a moisturizing cosmetic cream base for patients with atopic dermatitis during different seasons.

  K Kikuchi, H Tagami
  [show abstract] [hide abstract]
  ABSTRACT: The use of emollients is recommended for patients with atopic dermatitis (AD) to maintain improved condition. To ascertain objectively the effectiveness of a moisturizing cream for patients with AD during different seasons. We conducted clinical evaluations, noninvasive biophysical measurements and biochemical analyses of the stratum corneum (SC) components of the volar forearm skin of 23 patients with AD after a moisturizer was applied twice daily for 4 weeks. The moisturizer was formulated according to the consensus of cosmetic scientists belonging to major Japanese cosmetic companies. The nontreated forearm served as a control. After using the moisturizer treatment, the hydration of the SC significantly increased together with a decrease in the desquamation measurements and an improvement in the regularity of skin surface corneocytes. An improvement was observed in the SC barrier function in winter, but was achieved only after 4 weeks in late spring during which time there even occurred exacerbation of skin conditions in three patients. With use of the moisturizer treatment, we found no change in the SC content of free amino acids or ceramides, the ratio of interleukin (IL)-1 receptor antagonist to IL-1alpha, the ratio of immature to mature cornified envelopes, the size of the corneocytes or the emergence of parakeratotic cells in the skin surface corneocytes. Treatment with an adequate moisturizer is beneficial for the dry skin of patients with AD during the dry, cold season but it does not influence the impaired SC barrier function as effectively in the less arid season.
  British Journal of Dermatology 06/2008; 158(5):969-78.
• Article: IgA autoantibodies against the NC16a domain of BP180 but not 120-kDa LAD-1 detected in a patient with linear IgA disease.

  N Ishii, B Ohyama, Z Yamaguchi, T Hashimoto
  British Journal of Dermatology 06/2008; 158(5):1151-3.
• Article: Novel substitution and frameshift mutations of CYLD in two Chinese families with multiple familial trichoepithelioma.

  Y-H Liang, C-S Sun, X-Y Ye, W Zhang, S Yang, X-J Zhang
  British Journal of Dermatology 06/2008; 158(5):1156-8.
• Source

  Available from: b5z.net

  Article: Expert consensus: time for a change in the way we advise our patients to use topical corticosteroids.

  A Bewley
  [show abstract] [hide abstract]
  ABSTRACT: Topical corticosteroids form the mainstay of treatment for many skin conditions. If used appropriately, they are safe and effective, and side-effects are generally uncommon. Current advice to patients to apply topical corticosteroid preparations 'sparingly' or 'thinly' contributes to 'steroid phobia', increasing the risk of poor clinical response and treatment failure. Such cautionary advice also overlooks the fact that the vast majority of patients are prescribed topical corticosteroids of mild potency for which the evidence suggests that the risk of harm is minimal. In the patient's mind, the current advice groups all steroids together regardless of their potential for adverse effects. The advice also tends to reinforce an erroneous concern that the risks from topical corticosteroids may be similar to those from systemic corticosteroids. We propose a change to make the pharmacy labelling of topical corticosteroids more accurately reflect the low risk of harm from corticosteroids of low to moderate potency and the importance of applying sufficient medication to achieve a satisfactory clinical response. This change could provide the focus for updated, evidence-based education for healthcare professionals in prescribing of topical corticosteroids and help in the provision of more appropriate advice to patients. We recommend that patients are informed that treatment should not exceed prescribed quantities, and continuing treatment should be under careful medical supervision. We also recommend that topical corticosteroid products include clear 'fingertip unit' instructions, preferably with images of a 'fingertip unit' and a chart to show the number of units required for specific areas of the body.
  British Journal of Dermatology 06/2008; 158(5):917-20.
• Source

  Available from: anthonypapp.com

  Article: Beneficial effect of resin salve in treatment of severe pressure ulcers: a prospective, randomized and controlled multicentre trial.

  A Sipponen, J J Jokinen, P Sipponen, A Papp, S Sarna, J Lohi
  [show abstract] [hide abstract]
  ABSTRACT: Resin salve of the Norway spruce (Picea abies) has been used in folk medicine to heal wounds and infections. To study its clinical effectiveness in the treatment of pressure ulcers of the skin. A prospective, randomized, controlled multicentre trial involving 37 patients with grade II-IV pressure ulcers in 11 primary care hospitals was carried out between 2005 and 2007. The ulcers were randomly allocated to receive either resin salve or sodium carboxymethylcellulose hydrocolloid polymer treatment. The inclusion criterion was grade II-IV pressure ulcer. Exclusion criteria were a life expectancy of less than 6 months or a malignant disease. The primary outcome measure was complete healing of the ulcer within 6 months. Secondary outcome measures were partial healing of the ulcer, and successful eradication of bacterial strains cultured from the ulcers at study entry. Thirteen patients of the resin group and nine patients of the control group completed the 6-month trial. All ulcers healed in 12 of the 13 patients (92%) in the resin group and in four of the nine patients (44%) in the control group (P=0.003; power 73%). Complete healing of the ulcers over time was significantly more common in the resin group than in the control group (P=0.013). Bacterial cultures from the ulcer area more often became negative within 1 month in the resin group. Traditional resin salve is significantly more effective in the treatment of infected and noninfected severe pressure ulcers than cellulose polymer gauzes.
  British Journal of Dermatology 06/2008; 158(5):1055-62.